Literature DB >> 20490472

Effect of dose timing in relation to food intake on systemic exposure to blonanserin.

Junji Saruwatari1, Norio Yasui-Furukori, Yoshimasa Inoue, Sunao Kaneko.   

Abstract

PURPOSE: Blonanserin is a novel potent dopamine D(2) and serotonin 5-HT(2) antagonist for treating schizophrenia. The aim of this study was to investigate prandial effects on systemic exposure to blonanserin in healthy volunteers, with particular attention paid to the effect of dose timing relative to meal intake.
METHODS: Volunteers received a single 2-mg oral dose of blonanserin under the following conditions: fasting, 30 min before eating a standard meal; or 30 min or 2 or 4 h after eating the meal. Plasma concentrations of blonanserin were measured using validated high-performance liquid chromatography coupled with tandem mass spectrometry.
RESULTS: Ratios and 90% confidence intervals of the geometric means compared with the fasting condition indicated that the maximum concentrations of blonanserin (C(max)) significantly increased with dosing 30 min before meal intake, and 30 min and 2 and 4 h after meal intake, yielding by 330%, 239%, 272%, and 138%, respectively. The truncated area under the concentration-time curve (AUC(last)) also increased by 386%, 201%, 256%, and 155%, respectively. There was no difference in values of the time to reach maximum concentration between the fasting and the four fed states.
CONCLUSIONS: Food intake increased the systemic exposure to blonanserin for all time intervals investigated in this study. The marked effect of food on the bioavailability of blonanserin should be taken into account in its dosing schedules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490472     DOI: 10.1007/s00228-010-0834-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Effect of dietary fat content in meals on pharmacokinetics of quazepam.

Authors:  Norio Yasui-Furukori; Tsuyoshi Kondo; Takenori Takahata; Kazuo Mihara; Shingo Ono; Sunao Kaneko; Tomonori Tateishi
Journal:  J Clin Pharmacol       Date:  2002-12       Impact factor: 3.126

Review 3.  Monitoring adverse drug reactions: scales, profiles, and checklists.

Authors:  S Jordan; J Knight; D Pointon
Journal:  Int Nurs Rev       Date:  2004-12       Impact factor: 2.871

4.  Influence of food intake on the bioavailability and efficacy of oral calcitonin.

Authors:  Morten A Karsdal; Inger Byrjalsen; Möise Azria; Michel Arnold; Les Choi; Bente J Riis; Claus Christiansen
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

5.  Efficacy of blonanserin in combination therapy for treatment-resistant depression.

Authors:  Ryo Kumagai; Yosuke Ichimiya
Journal:  Psychiatry Clin Neurosci       Date:  2009-08       Impact factor: 5.188

6.  AD-5423 Dainippon Pharmaceutical Co Ltd.

Authors:  C E Heading
Journal:  IDrugs       Date:  1998-11

Review 7.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

8.  Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate.

Authors:  Wonku Kang; Kibum Kim; Eun-Young Kim; Kwang-il Kwon; Jun Seok Bang; Young-Ran Yoon
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

9.  Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.

Authors:  Mark B Sostek; Yusong Chen; Tommy Andersson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

10.  The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Authors:  Esther Garcia; Marta Robert; Francesc Peris; Hiroshi Nakamura; Noriko Sato; Yoshikatsu Terazawa
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more
  9 in total

1.  Blonanserin's interesting food-effect observations: is lymphatic transport involved?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2011-04-06       Impact factor: 2.953

Review 2.  Newer antipsychotics and upcoming molecules for schizophrenia.

Authors:  Melvin George; Radhika Amrutheshwar; Ravi Philip Rajkumar; Shivanand Kattimani; Steven Aibor Dkhar
Journal:  Eur J Clin Pharmacol       Date:  2013-04-02       Impact factor: 2.953

Review 3.  Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.

Authors:  Mirko Koziolek; Frédéric Carrière; Christopher J H Porter
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

4.  The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses.

Authors:  Xia Chen; Hongyun Wang; Ji Jiang; Rui Chen; Ying Zhou; Wen Zhong; Hongzhong Liu; Pei Hu
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

5.  Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.

Authors:  De-Wei Shang; Zhan-Zhang Wang; Hai-Tang Hu; Yue-Feng Zhang; Xiao-Jia Ni; Hao-Yang Lu; Ming Zhang; Jin-Qing Hu; Chang Qiu; Huan Peng; Ling-Fang Shen; Yu-Guan Wen
Journal:  Eur J Clin Pharmacol       Date:  2017-10-03       Impact factor: 2.953

6.  Simple and sensitive analysis of blonanserin and blonanserin C in human plasma by liquid chromatography tandem mass spectrometry and its application.

Authors:  Yunliang Zheng; Xingjiang Hu; Jian Liu; Guolan Wu; Huili Zhou; Meixiang Zhu; You Zhai; Lihua Wu; Jianzhong Shentu
Journal:  J Anal Methods Chem       Date:  2014-02-11       Impact factor: 2.193

7.  Profile of blonanserin for the treatment of schizophrenia.

Authors:  Tomomi Tenjin; Seiya Miyamoto; Yuriko Ninomiya; Rei Kitajima; Shin Ogino; Nobumi Miyake; Noboru Yamaguchi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-29       Impact factor: 2.570

8.  Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.

Authors:  Amane Tateno; Takeshi Sakayori; Woo-Chan Kim; Kazuyoshi Honjo; Haruo Nakayama; Ryosuke Arakawa; Yoshiro Okubo
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

9.  Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.

Authors:  Shintaro Sakai; Yoshiro Morimoto; Yusuke Matsuzaka; Takeshi Nakano; Shinji Kanegae; Akira Imamura; Hiroki Ozawa
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.